Literature DB >> 3117150

Changes in blood gas levels after nebuhaler and nebulizer administration of terbutaline in severe chronic airway obstruction.

R M Higgins1, W O Cookson, G A Chadwick.   

Abstract

It has been suggested that patients with severe chronic airway obstruction might suffer dangerous hypoxia after administration of a beta-agonist through an air driven nebulizer. Twenty patients with severe chronic airway obstruction (12 male, mean age 71.1 (SEM 1.5) yr) were monitored with a Biox oximeter and Hewlett-Packard capnometer before and after 4 mg terbutaline was delivered through an air driven nebulizer or Nebuhaler. The eight patients with chronic hypoxia (mean PaO2 6.76 kPa, PaCO2 7.47 kPa. FEV1 0.53 l) experienced a 4.7% increase in oxygen saturation (SaO2) and 2.9% fall in transcutaneous carbon dioxide tension (PtcCO2) (p less than 0.05) during all treatments, followed by a return to initial levels. These changes were attributable to increased ventilation whilst breathing through a mouthpiece. A similar trend was seen in the SaO2 of the twelve normoxic patients (mean PaO2 9.32 kPa, PaCO2 5.34 kPa, FEV1 0.8 l), but there was a sustained fall in PtcCO2 of 3.7% (p less than 0.001) after administration of terbutaline. Inhaled terbutaline in the dosage given did not cause hypoxia in patients with severe chronic airflow obstruction, but nebulizer and Nebuhaler use was associated with a rise in SaO2 related to increased ventilation whilst breathing through a mouthpiece.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117150

Source DB:  PubMed          Journal:  Bull Eur Physiopathol Respir        ISSN: 0395-3890


  4 in total

Review 1.  Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD).

Authors:  J Wright; D Brocklebank; F Ram
Journal:  Qual Saf Health Care       Date:  2002-12

Review 2.  Nebulisers for the elderly.

Authors:  J C Pounsford
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 3.  Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence.

Authors:  Ken M Kunisaki; Kathryn L Rice; Dennis E Niewoehner
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 4.  Severe chronic obstructive pulmonary disease.

Authors:  Ken Y Yoneda; Richart W Harper; Samuel Louie
Journal:  Clin Rev Allergy Immunol       Date:  2003-10       Impact factor: 8.667

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.